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OBJECTIVES: To describe the relationship between symptoms
of gastroesophageal reﬂux disease (GERD) and costs for work
productivity loss, physician/specialist visits, emergency room
visits, hospitalisations, and prescribed GERD-related medica-
tion. METHODS: An exploratory database analysis was per-
formed on results from the 2004 National Health and Wellness
Survey. US respondents with self-reported symptoms of GERD
(n = 10,028, mean age: 52 years, 58% female) were age- and
sex-matched to controls without GERD symptoms (n = 10,028).
Respondents with GERD were classiﬁed by self-reported
symptom severity (mild, moderate or severe) and frequency (low
or medium-to-high: symptoms on <2 days or ≥2 days per week,
respectively). Productivity losses (absence from work and
reduced productivity while at work) were obtained using the
generic version of the Work Productivity and Activity Impair-
ment questionnaire, and were calculated as the mean difference
between employed respondents with GERD (n = 5505) and con-
trols (n = 6031). Costs were calculated by multiplying ﬁxed
approximate unit costs by self-reported productivity losses and
resource utilisation. RESULTS: Compared with controls, respon-
dents with GERD had greater costs per month for absence from
work (mean difference [MD]: $113 per employee), reduced pro-
ductivity while at work (MD: $283 per employee), physician/spe-
cialist visits (MD:$45), emergency room visits (MD: $7), and
hospitalisations (MD: $30). Monthly GERD-related medication
costs for respondents with GERD were $42. The mean differ-
ences in costs increased with increasing GERD symptom sever-
ity and/or frequency for all cost variables. The relative cost of
GERD medication decreased with increasing symptoms: for
example, when excluding productivity costs, GERD medication
constituted 40% of the mean difference in overall monthly costs
in patients with mild symptoms and a low frequency, but only
25% in patients with severe symptoms and a medium-to-high
frequency. CONCLUSION: Increasing severity and frequency of
GERD symptoms was found to be associated with higher overall
costs, while the relative importance of GERD medication costs
decreased.
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OBJECTIVES: On May 18, 2005 the Arkansas Medicaid
program implemented an evidence-based Preferred Drug List
(PDL) recommendation for Proton Pump Inhibitors (PPIs).
Under the PDL program guidelines, esomeprazole and lansopra-
zole were made available as preferred agents to Medicaid recip-
ients without prior approval. Previously, all PPIs required prior
authorization and were not covered unless patients The objec-
tive of this study was to estimate the impact of this policy on PPI
expenditures and utilization as well as utilization of potential
substitute H2RAs. METHODS: This study utilized a time series
panel design to evaluate the impact of the policy using Arkansas
Medicaid administrative claims data obtained from January
2003 through August 2006. Auto-Regressive Integrated Moving
Average (ARIMA) time series models were speciﬁed using
monthly prescription expenditures and utilization in the pre-
policy period (January 2003–April 2005) to forecast expen-
ditures and utilization in the post-policy period. The Medicaid
payer perspective was used and all prescription costs were 
calculated based on the amount paid for each claim adjusted 
for product speciﬁc CMS rebates. RESULTS: The annual 
forecast expenditures for PPIs and H2RAs collectively for 
June 2005–May 2006 was $9,432,605 (95%CI: 8,747,983–
10,117,226) and observed expenditures were $4,555,592 indi-
cating that the prior approval policy change was associated with
a 52% reduction in GI antisecretory expenditures or $4,877,013
(95%CI: 4,192,391–5,561,635). Utilization of PPIs increased by
44% (3001 Rxs/month; 95%CI: 3695–2308) which more than
offset the 21% (1660 Rxs/month; 95%CI: 1199–2121) decrease
in utilization of H2RAs. CONCLUSION: Replacing step therapy
and prior authorization requirements with a preferred drug list
selection including supplemental rebates for this Medicaid
program signiﬁcantly lowered expected combined H2RA and
PPI prescription expenditures. Since utilization to antisecretory
therapy actually increased, increases in non-pharmacy costs or
negative outcomes are not anticipated.
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OBJECTIVES: Hospitalization is a major source of health care
costs for Crohn’s Disease (CD). This retrospective analysis of
clinical trial data examined the relationship between Crohn’s
Disease Activity Index (CDAI) scores and hospitalization risk.
METHODS: We analyzed data from the CHARM trial (adali-
mumab maintenance therapy) for 778 randomized patients (of
854 enrolled) with moderate to severe CD (baseline CDAI:
220–450) who were treated for up to 66 weeks. As a measure
of clinical efﬁcacy, CDAI scores were collected. Hospitalization
events were recorded as severe adverse events. While controlling
for patient demographic information, we applied a Cox propor-
tional hazard regression model to evaluate the relationship
between hospitalization risk and CDAI reduction or clinical
remission (CDAI < 150). CDAI and clinical remission were
imputed as time-varying covariates. Simulation was applied to
assess 1-year, all-cause and CD-related hospitalization rates.
RESULTS: A total of 157 patients were hospitalized, of which
112 were for CD-related reasons. Cox regression revealed that,
at any point in time, lower CDAI score was associated with
decreased risk of both all-cause hospitalization (hazard ratio
[HR] = 1.06 for every 10 points of CDAI increase, p < 0.01) and
CD-related hospitalization (HR = 1.08, p < 0.01). Simulation
study showed that a 70-point CDAI reduction throughout the
follow-up period reduced all-cause hospitalization risk by 28.3%
and CD-related hospitalization risk by 36.5% at year-end. Clin-
ical remission was associated with a signiﬁcant reduction in both
all-cause (HR = 0.52, p < .001) and CD-related hospitalizations
(HR = 0.37, p < .001). Simulations revealed that clinical remis-
sion was associated with a 43.7% decrease in the 1-year risk of
all-cause hospitalization and a 60.3% decrease in CD-related
hospitalization. CONCLUSION: Both lower CDAI score and
clinical remission are associated with signiﬁcantly reduced hos-
pitalization risk for CD patients.
